JP2016518833A5 - - Google Patents

Download PDF

Info

Publication number
JP2016518833A5
JP2016518833A5 JP2016509127A JP2016509127A JP2016518833A5 JP 2016518833 A5 JP2016518833 A5 JP 2016518833A5 JP 2016509127 A JP2016509127 A JP 2016509127A JP 2016509127 A JP2016509127 A JP 2016509127A JP 2016518833 A5 JP2016518833 A5 JP 2016518833A5
Authority
JP
Japan
Prior art keywords
protein
isomerase
extract
exogenous
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016509127A
Other languages
English (en)
Japanese (ja)
Other versions
JP6463732B2 (ja
JP2016518833A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/034643 external-priority patent/WO2014172631A2/en
Publication of JP2016518833A publication Critical patent/JP2016518833A/ja
Publication of JP2016518833A5 publication Critical patent/JP2016518833A5/ja
Application granted granted Critical
Publication of JP6463732B2 publication Critical patent/JP6463732B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016509127A 2013-04-19 2014-04-18 上昇したレベルの外因性シャペロンを有する細胞抽出物を用いる細菌無細胞合成系における生物活性のあるタンパク質の発現 Active JP6463732B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361813914P 2013-04-19 2013-04-19
US61/813,914 2013-04-19
US201461937069P 2014-02-07 2014-02-07
US61/937,069 2014-02-07
PCT/US2014/034643 WO2014172631A2 (en) 2013-04-19 2014-04-18 Expression of biologically active proteins in a bacterial cell-free synthesis system using bacterial cells transformed to exhibit elevated levels of chaperone expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018136909A Division JP2018157837A (ja) 2013-04-19 2018-07-20 上昇したレベルの外因性シャペロンを有する細胞抽出物を用いる細菌無細胞合成系における生物活性のあるタンパク質の発現

Publications (3)

Publication Number Publication Date
JP2016518833A JP2016518833A (ja) 2016-06-30
JP2016518833A5 true JP2016518833A5 (enExample) 2017-07-20
JP6463732B2 JP6463732B2 (ja) 2019-02-06

Family

ID=50733442

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016509127A Active JP6463732B2 (ja) 2013-04-19 2014-04-18 上昇したレベルの外因性シャペロンを有する細胞抽出物を用いる細菌無細胞合成系における生物活性のあるタンパク質の発現
JP2018136909A Withdrawn JP2018157837A (ja) 2013-04-19 2018-07-20 上昇したレベルの外因性シャペロンを有する細胞抽出物を用いる細菌無細胞合成系における生物活性のあるタンパク質の発現

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018136909A Withdrawn JP2018157837A (ja) 2013-04-19 2018-07-20 上昇したレベルの外因性シャペロンを有する細胞抽出物を用いる細菌無細胞合成系における生物活性のあるタンパク質の発現

Country Status (13)

Country Link
US (3) US10190145B2 (enExample)
EP (1) EP2986731B1 (enExample)
JP (2) JP6463732B2 (enExample)
KR (1) KR102289258B1 (enExample)
CN (1) CN105283556B (enExample)
AU (1) AU2014253785B2 (enExample)
CA (1) CA2909516C (enExample)
DK (1) DK2986731T3 (enExample)
ES (1) ES2922358T3 (enExample)
HU (1) HUE059565T2 (enExample)
IL (1) IL242148B (enExample)
SG (2) SG10202108497TA (enExample)
WO (1) WO2014172631A2 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE059565T2 (hu) * 2013-04-19 2022-11-28 Sutro Biopharma Inc Biológiailag aktív fehérjék expressziója bakteriális sejtmentes szintézisrendszerben, emelkedett exogén chaperonszintû sejtextraktumok segítségével
US10316322B2 (en) * 2014-07-02 2019-06-11 Sutro Biopharma, Inc. High growth capacity auxotrophic Escherichia coli and methods of use
WO2016073794A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Methods of producing two chain proteins in bacteria
WO2016073791A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Methods of producing two chain proteins in bacteria
WO2016100889A1 (en) * 2014-12-19 2016-06-23 Sutro Biopharma, Inc. Codon optimization for titer and fidelity improvement
KR102489471B1 (ko) 2014-12-30 2023-01-18 셀진 코포레이션 항-cd47 항체 및 그 용도
SI3265557T1 (sl) * 2015-03-06 2020-02-28 F. Hoffmann-La Roche Ag Ultraprečiščena DsbA in DsbC ter postopki njune izdelave in uporabe
US20170029798A1 (en) * 2015-07-27 2017-02-02 Cellivery Therapeutics, Inc. Development of Improved Cell-Permeable (iCP) Parkin Recombinant Protein as a Protein-Based Anti-Neurodegenerative Agent for the Treatment of Parkinson's Disease-Associated Phenotypes by Utilizing BBB-Penetrating Protein Delivery System MITT, Enabled by Advanced Macromolecule Transduction Domain (aMTD)
MX2018002068A (es) * 2015-08-20 2018-06-06 Genentech Inc Purificacion de fkpa y usos de la misma para producir polipeptidos recombinantes.
CN105198983B (zh) * 2015-09-11 2018-11-06 中国石油大学(华东) 一种利于七次跨膜蛋白ccr5功能性表达的方法
CN106190940B (zh) * 2016-07-19 2019-06-14 北京三元基因药业股份有限公司 表达抗TNF抗体Fab片段的重组大肠杆菌工程菌
CN106399352B (zh) * 2016-11-09 2020-04-17 华东理工大学 调节目标蛋白表达的折叠因子及其应用
DK3562940T3 (da) * 2016-12-30 2022-07-11 Natures Toolbox Inc Cellefrit ekspressionssystem med hidtil ukendt, uorganisk polyphosphatbaseret energiregeneration
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
KR20240110660A (ko) 2016-12-30 2024-07-15 박사이트, 인코포레이티드 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체
US12227778B2 (en) 2016-12-30 2025-02-18 Nature's Toolbox, Inc. Cell-free expression system having novel inorganic polyphosphate-based energy regeneration
AR112756A1 (es) 2017-07-11 2019-12-11 Synthorx Inc Incorporación de nucleótidos no naturales, y su método
MX2020001336A (es) 2017-08-03 2020-08-20 Synthorx Inc Conjugados de citoquina para el tratamiento de enfermedades autoinmunes.
US20200181670A1 (en) * 2017-08-11 2020-06-11 Synvitrobio, Inc. Improved In Vitro Transcription/Translation (TXTL) System and Use Thereof
WO2019127469A1 (zh) * 2017-12-29 2019-07-04 康码(上海)生物科技有限公司 一种高效的能源再生体系(bes)、试剂盒及其制备方法
TWI834636B (zh) 2018-02-26 2024-03-11 美商欣爍克斯公司 Il-15結合物及其用途
WO2020014543A2 (en) * 2018-07-11 2020-01-16 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
WO2020096959A1 (en) * 2018-11-05 2020-05-14 Genentech, Inc. Methods of producing two chain proteins in prokaryotic host cells
JP7426389B2 (ja) * 2018-11-08 2024-02-01 ストロ バイオファーマ, インコーポレイテッド 酸化的細胞質を有する大腸菌株
JP7636323B2 (ja) 2018-11-08 2025-02-26 シンソークス, インコーポレイテッド インターロイキン10コンジュゲートおよびその使用
CN109371049A (zh) * 2018-11-14 2019-02-22 天津大学 分子伴侣在促进单克隆抗体的形成和/或提高单克隆抗体的表达量中的应用
JP7702872B2 (ja) 2019-02-06 2025-07-04 シンソークス, インコーポレイテッド Il-2コンジュゲートおよびその使用方法
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
CA3150163A1 (en) 2019-08-15 2021-02-18 Synthorx, Inc. Immuno oncology combination therapies with il-2 conjugates
TW202124385A (zh) 2019-09-10 2021-07-01 美商欣爍克斯公司 治療自體免疫疾病之il-2接合物及使用方法
MX2022005251A (es) 2019-11-04 2022-06-08 Synthorx Inc Conjugados de interleuquina 10 y sus usos.
EP4056584A4 (en) * 2019-11-08 2024-06-05 Korea Institute of Ocean Science & Technology NOVEL HUMAN EPIDERMAL GROWTH FACTOR-TF FUSION PROTEIN AND USE THEREOF
EP4114931A4 (en) * 2020-03-05 2024-05-01 Curie Co. Inc. METHODS FOR CELL PROTEIN EXPRESSION OF MATURE POLYPEPTIDES DERIVED FROM ZYMOGENS AND PROPROTEINS
CA3175683A1 (en) * 2020-04-29 2021-11-04 Xueyang FENG Compositions and methods for enhancing recombinant biosynthesis of cannabinoids
BR112022026236A2 (pt) 2020-06-25 2023-01-17 Synthorx Inc Terapia de combinação de imuno-oncologia com conjugados de il-2 e anticorpos anti-egfr
KR20220000028U (ko) 2020-06-29 2022-01-05 채인자 농작물용 농약 간편 분무장치
US20220089690A1 (en) * 2020-09-14 2022-03-24 Sutro Biopharma, Inc. Method for large scale production of antibodies using a cell-free protein synthesis system
IL301612A (en) 2020-10-09 2023-05-01 Synthorx Inc Immuno oncology therapies with il-2 conjugates
BR112023006364A2 (pt) 2020-10-09 2023-05-09 Synthorx Inc Terapia de combinação de imuno-oncologia com conjugados de il-2 e pembrolizumabe
WO2022174101A1 (en) 2021-02-12 2022-08-18 Synthorx, Inc. Skin cancer combination therapy with il-2 conjugates and cemiplimab
EP4291243A1 (en) 2021-02-12 2023-12-20 Synthorx, Inc. Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
EP4346903A1 (en) 2021-06-03 2024-04-10 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
EP4452327A1 (en) 2021-12-20 2024-10-30 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2023122750A1 (en) 2021-12-23 2023-06-29 Synthorx, Inc. Cancer combination therapy with il-2 conjugates and cetuximab
CA3255881A1 (en) * 2022-06-17 2023-12-21 Insitro Inc In situ sequencing of RNA transcripts with non-uniform 5' ends
CN115028691B (zh) * 2022-06-29 2024-09-10 青岛硕景生物科技有限公司 一种检测试纸用的独立质控系统、杂交瘤细胞株、质控线用包被单克隆抗体及其应用
WO2024136899A1 (en) 2022-12-21 2024-06-27 Synthorx, Inc. Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
WO2024196937A1 (en) 2023-03-20 2024-09-26 Synthorx, Inc. Cancer therapy with il-2 peg conjugates
CN116925196B (zh) * 2023-06-08 2025-04-18 齐鲁工业大学(山东省科学院) 小分子热休克蛋白rsp_1572在提高宿主菌环境耐受性中的应用
WO2025158385A1 (en) 2024-01-25 2025-07-31 Genzyme Corporation Pegylated il-2 for suppressing adaptive immune response to gene therapy
CN118048325B (zh) * 2024-04-16 2024-07-16 天津凯莱英生物科技有限公司 酶的高通量筛选方法及酶库的构建方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10145694A1 (de) 2001-09-17 2003-04-03 Roche Diagnostics Gmbh Verfahren zur Erhöhung der Löslichkeit, der Expressionsrate und der Aktivität von Proteinen während der rekombinanten Herstellung
WO2004081033A2 (en) * 2003-03-11 2004-09-23 National Institutes Of Health Synthesis of proteins by cell-free protein expression
JP2005253432A (ja) 2004-03-15 2005-09-22 Sekisui Chem Co Ltd タンパク質の生産方法、並びにそれに使用するための組成物、試薬及びキット
JP4561243B2 (ja) 2004-08-27 2010-10-13 株式会社豊田中央研究所 無細胞タンパク質合成系のための媒体
AU2007325952B8 (en) * 2006-06-29 2013-06-27 The Board Of Trustees Of The Leland Stanford Junior University Cell-free synthesis of proteins containing unnatural amino acids
CA2673765A1 (en) * 2007-01-18 2008-07-24 The Board Of Trustees Of The Leland Stanford Junior University Enhanced cell-free synthesis of active proteins containing disulfide bonds
CN102348807B (zh) 2009-01-12 2015-04-15 苏特罗生物制药公司 利用体外蛋白合成体系将非天然氨基酸引入蛋白的单装载体系
CN102732548A (zh) 2012-05-16 2012-10-17 中国农业大学 一种表达蛇毒激肽原酶的高效麦胚无细胞蛋白合成系统的建立及应用
JP6421122B2 (ja) * 2012-10-12 2018-11-07 ストロ バイオファーマ, インコーポレイテッド 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化
HUE059565T2 (hu) 2013-04-19 2022-11-28 Sutro Biopharma Inc Biológiailag aktív fehérjék expressziója bakteriális sejtmentes szintézisrendszerben, emelkedett exogén chaperonszintû sejtextraktumok segítségével

Similar Documents

Publication Publication Date Title
JP2016518833A5 (enExample)
WO2014172631A4 (en) Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones
Bhatwa et al. Challenges associated with the formation of recombinant protein inclusion bodies in Escherichia coli and strategies to address them for industrial applications
Kinney et al. Elucidating essential role of conserved carboxysomal protein CcmN reveals common feature of bacterial microcompartment assembly
Ferrer-Miralles et al. General introduction: recombinant protein production and purification of insoluble proteins
Gasser et al. Protein folding and conformational stress in microbial cells producing recombinant proteins: a host comparative overview
Oganesyan et al. Effect of osmotic stress and heat shock in recombinant protein overexpression and crystallization
Katzke et al. A novel T7 RNA polymerase dependent expression system for high-level protein production in the phototrophic bacterium Rhodobacter capsulatus
Sarkari et al. Improved expression of single-chain antibodies in Ustilago maydis
JP2021506328A (ja) 発酵プロセス
Ukkonen et al. Use of slow glucose feeding as supporting carbon source in lactose autoinduction medium improves the robustness of protein expression at different aeration conditions
Sun et al. Enhanced production of recombinant proteins in Corynebacterium glutamicum by constructing a bicistronic gene expression system
CN104611396B (zh) 一种生产谷胱甘肽的方法
JP2017517257A5 (enExample)
Skretas et al. Multi-copy genes that enhance the yield of mammalian G protein-coupled receptors in Escherichia coli
Liu et al. Efficient extracellular production of κ-carrageenase in Escherichia coli: Effects of wild-type signal sequence and process conditions on extracellular secretion
Ahn et al. Improved recombinant protein production using heat shock proteins in Escherichia coli
Tan et al. The role of lac operon and lac repressor in the induction using lactose for the expression of periplasmic human interferon-α2b by Escherichia coli
Mohammadinezhad et al. Efficient osmolyte-based procedure to increase expression level and solubility of infectious hematopoietic necrosis virus (IHNV) nucleoprotein in E. coli
KR20170105079A (ko) 천연 또는 가공된 진핵 세포의 생리에 긍정적으로 영향을 미치는 박테리아 샤페론의 조합물
JP2014512814A (ja) 大腸菌での異種タンパク質生成のための新規発現および分泌ベクター系
Cho et al. Maltose binding protein facilitates high-level expression and functional purification of the chemokines RANTES and SDF-1α from Escherichia coli
Niu et al. The molecular design of a recombinant antimicrobial peptide CP and its in vitro activity
CN103333912B (zh) 在Pichia pastoris中组成型表达菌丝霉素衍生物MP1102的方法
Song et al. The response regulator Slr1588 regulates spsA but is not crucial for salt acclimation of Synechocystis sp. PCC 6803